Cytokinetics(CYTK)
Focus: Cytokinetics is a publicly traded small-molecule biotech focused on cardiac and neuromuscular diseases, with one FDA-approved product (Myqorzo/aficamten) recently launched for hypertrophic cardiomyopathy. The company is pre-peak stage with significant R&D investment and a diversified pipeline across cardiovascular, neurology, oncology, rare disease, and respiratory indications.
Profile data last refreshed 7h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
53+20 this month
Hot — 39 jobs added in 30d
Net +20 (39 new, 19 removed). Aggressive expansion phase.
Should You Work at Cytokinetics?
AI assessmentBest suited for risk-tolerant candidates seeking high-growth early commercial execution and pipeline depth, with awareness that clinical/commercial success is critical to long-term stability.
Why Work Here
- Recent public offering ($805M raised May 2026) and FDA approval of Myqorzo signals strong momentum and cash runway to execute on pipeline expansion.
Data completeness
7/9 — Strong
Company HealthStrong
Pipeline
Late-stage
11 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$8M
Key Products
Launch16.1yr
First-in-class cardiac myosin inhibitor approved for HCM; landmark indication with significant unmet need and patent protection to 2042.
Help build intelligence for Cytokinetics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.